Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus price objective of $26.75 for the company, according to Zacks. Zacks has also given Verona Pharma PLC American Depositary Share an industry rank of 107 out of 265 based on the ratings given to related companies.

A number of research firms have recently commented on VRNA. Zacks Investment Research cut shares of Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Verona Pharma PLC American Depositary Share in a report on Friday, September 8th.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ VRNA) traded up 2.295% during midday trading on Friday, hitting $15.375. 4,371 shares of the stock were exchanged. The stock’s market cap is $170.11 million. The firm has a 50 day moving average of $13.26 and a 200-day moving average of $13.77. Verona Pharma PLC American Depositary Share has a 12 month low of $11.03 and a 12 month high of $17.50.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.09). Equities research analysts anticipate that Verona Pharma PLC American Depositary Share will post ($2.23) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/23/zacks-verona-pharma-plc-american-depositary-share-vrna-given-26-75-consensus-price-target-by-analysts.html.

Large investors have recently added to or reduced their stakes in the company. FIL Ltd bought a new stake in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter valued at about $873,000. Tekla Capital Management LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter valued at about $3,211,000. Finally, Vivo Capital LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter valued at about $8,208,000. Institutional investors and hedge funds own 30.16% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.